Use of positron emission tomography in anticancer drug development

Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enh...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 2003-05, Vol.21 (2), p.169-181
Main Authors: Aboagye, Eric O, Price, Patricia M
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - blood
Antineoplastic Agents - metabolism
Cancer
Dosimetry
Drug development
Drug dosages
Humans
Kinetics
Liver
Localization
Metastasis
Models, Biological
Pharmacodynamics
Pharmacokinetics
Physiology
Plasma
Technology, Pharmaceutical - methods
Tomography
Tomography, Emission-Computed - methods
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[11C]thymidine, [18F]fluorodeoxyglucose, H2(15)O, C15O, and receptor ligands.
ISSN:0167-6997
1573-0646
DOI:10.1023/A:1023521412787